Page 13 - Stat Facts News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research Institute February 2, 2021 GMT TOKYO & MUNICH & BASKING RIDGE, N.J. & NASHVILLE, Tenn.--(BUSINESS WIRE)--Feb 2, 2021-- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute (Sarah Cannon) announced today that the first patient has been dosed in the first-in-human phase 1 study evaluating DS-6000, a CDH6 directed antibody drug conjugate (ADC), in patients with adv...

1 1,2 as a standard of care for intermediate- or poor-risk patients 3 OPDIVO ® (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with CABOMETYX ® (cabozantinib) 40 mg once daily tablets was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). 1 The approval is based on the Phase 3 CheckMate -9ER trial, which compared OPDIVO in combination with CABOMETYX (n=323) versus sunitinib (n=328) in patients with advanced RCC. 1 Thi...

Trashing this as a, quote, witch hunt. that banner is accurataccurate, sense the president said it. i also have to report, chris, it's pretty hard to understand. this so-called witch hunt in the president's words is a decision that was made by the person he just picked to be deputy attorney general, rosenstein, who he only picked a few weeks ago. it is far less likely this is a witch hunt designed to somehow get someone. that's how we think of a witch hunt. far more likely, i think, at this juncture, the deputy attorney general looked tat facts, looked at the appearance of conflicts, that's wh...